Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: falling victim to sentiment

October 1, 2019 8:21pm

The IBB closed down -1.50% while the XBI closed down -1.64% as 19 out of the 36 downside had higher than the 3 month average volume

And the NASDAQ had its wings clipped in the first session of Q4

I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.

There are a variety of end uses to sector forecasts; the most prominent, they are used to protect your portfolio’s life and value.

The Dow closed down -343.79 (-1.28%), the S&P closed down -36.49 (-1.23%) and the NASDAQ closed down -36.49 (-1.13%)

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Tuesday the IBB closed down -1.50% while the XBI closed down -1.64%
Monday the IBB closed up +0.20% while the XBI closed down -0.21%
Friday the IBB closed down -0.78% while the XBI closed down -0.59%

Henry’omics:

Sector equities got hammered on Tuesday, the first trading day of Q4, as disappointing manufacturing data stoked worries over the U.S. economy with the Nasdaq depressed -1.13%.

... Marking the worst one-day performance for the Dow and S&P 500 since Aug. 23. That day, the two indexes fell more than 2% each

The Institute for Supply Management said U.S. manufacturing activity contracted to its worst level since June 2009. The ISM report follows the release of weak manufacturing data from Europe.

The volatility we’re seeing is reflective of the fact that sentiment echoes into momentum and trust affecting “our’ universe is deeper than expected based nationally and they’re globally changing day to day,

The advance/decline line scenario of 45 covered companies:

Tuesday's close was negative with an A/D line of 5/36, 2 flats and 2 acquired;
Monday the close was positive with an A/D line of 21/19, 3 flats and 2 acquired;
Friday the close was negative with an A/D line of 14/27, 2 flats and 2 acquired;

Decliners:

Alnylam Pharmaceuticals (ALNY -$5.91)
Bluebird bio (BLUE -$4.80 after Monday’s -$0.99. Friday’s -$3.02 after Thursday’s +$9.29);
Sage Therapeutics (SAGE -$4.01 after Monday’s -$2.46);
Ions Pharmaceuticals (IONS -$2.77 after Monday’s +$0.85);
BioMarin Pharmaceuticals (BMRN -$2.54 after Monday’s -$0.91, Friday’s -$2.91);

Incliners:

ReNeuron (RENE.L -$20.00 after Monday’s +$17.50, Friday’s +$17.50 and Thursday’s +$15.00);
Cellectis (CLLS +$0.73);
Caladrius Biosciences (CLBS +$0.12);
Neuralstem (CUR +$0.02);
Organovo (ONVO +$0.0038);

The percentage (%) indicators:

Tuesday’s range of the 5 upside was +1.20% (CUR) to +8% (RENE.L) while the 36 downside ranged from -0.13% (ONCE) to -9.62% (BSTG);
Monday’s range of the 21 upside was +0.22% (FIXX) to +7.53% (RENE.L) while the 20 downside ranged from -0.43% (QURE) to -30.65% (HSGX);
Friday’s range of the 14 upside was +0.12% (RGNX) to +8.14% (RENE.L) while the 27 downside ranged from -0.30% (BOLD) to -30.65% (HSGX);

Upside volume stats: to compare

Tuesday: 3 out of the 5 upside had higher than the 3 month average volume;
Monday: 9 out of the 21 upside had higher than the 3 month average volume;
Friday: 4 out of the 14 upside had higher than the 3 month average volume;

Downside volume stats:

Tuesday: 19 out of the 36 downside had higher than the 3 month average volume;
Monday: 4 out of the 19 downside had higher than the 3 month average volume;
Friday: 13 out of the 27 downside had higher than the 3 month average volume;

2 flat – MDXG and MESO with 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche is still being delayed (October?)

October’s sessions:

Tuesday closed NEGATIVE with 36 decliners, 5 advancers, 2 flat and 2 acquired (AST & OSIR);

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

48 min ago
RMi pre-open: Check light

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.